期刊
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
卷 16, 期 3, 页码 424-442出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijms.30154
关键词
Histone deacetylases (HDACs); T-cell lymphomas; cutaneous T-cell lymphoma; peripheral T-cell lymphoma; combination therapy
资金
- Sanming Projects of Medicine in Shenzhen [SZSM201612071]
- Shenzhen Foundation of Science and Technology [JCYJ20170306091928754, JCYJ201708 16105345191]
- Shenzhen Foundation of Health and Family Planning Commission [SZBC2017028]
T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate many key biological processes. In recent years, HDACs have been fully investigated for their roles and potential as drug targets in T-cell lymphomas. In this review, we have deciphered the modes of action of HDACs, HDAC inhibitors as single agents, and HDACs guided combination therapies in T-cell lymphomas. The overview of HDACs on the stage of T-cell lymphomas, and HDACs guided therapies both as single agents and combination regimens endow great opportunities for the cure of T-cell lymphomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据